SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases
10.1007/s12640-012-9358-z · doi-reference
The role of post-translational modifications of huntingtin in the pathogenesis of Huntington’s disease
10.1007/s12264-010-1118-6 · doi-reference
SUMOylation and deSUMOylation at a glance
10.1242/jcs.050542 · doi-reference
Molecular mechanisms in SUMO conjugation
10.1042/bst20190357 · doi-reference
Body weight is a robust predictor of clinical progression in Huntington disease
10.1002/ana.25007 · doi-reference
Beyond the brain: widespread pathology in Huntington’s disease
10.1016/s1474-4422(09)70178-4 · doi-reference
Inflammation in Huntington’s disease: a few new twists on an old tale
10.1016/j.jneuroim.2020.577380 · doi-reference
Enhanced SUMOylation in polyglutamine diseases
10.1016/s0006-291x(02)00211-5 · doi-reference
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome
10.1083/jcb.200909067 · doi-reference
Huntington disease: a quarter century of progress since the gene discovery
10.1016/j.jns.2018.09.022 · doi-reference
SUMO-1 co-localized with mutant atrophin-I with expanded polyglutamines accelerates intranuclear aggregation and cell death
10.1097/00001756-200212030-00038 · doi-reference
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
10.1038/s41582-020-0389-4 · doi-reference
Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington’s disease
10.1016/j.nbd.2015.05.011 · doi-reference
Huntington’s disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum)
10.1016/j.neuropharm.2010.10.025 · doi-reference
Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity
10.1126/science.1172871 · doi-reference
Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9
10.1074/jbc.c110.127191 · doi-reference
SUMO modification of huntingtin and Huntington’s disease pathology
10.1126/science.1092194 · doi-reference
Does huntingtin play a role in selective macroautophagy?
10.4161/cc.9.17.12718 · doi-reference
Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’ s disease
10.1093/hmg/ddr475 · doi-reference
SUMO proteins in the cardiovascular system: friend or foe?
10.1186/s12929-020-00689-0 · doi-reference
Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion
10.1083/jcb.201807068 · doi-reference
Involvement of the protein ras homolog enriched in the striatum, rhes, in dopaminergic neurons’ degeneration: link to Parkinson’s disease
10.3390/ijms22105326 · doi-reference
SUMOylation prevents huntingtin fibrillization and localization onto lipid membranes
10.1021/acschemneuro.9b00509 · doi-reference
Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review
10.3390/brainsci10040232 · doi-reference
SUMO and its role in human diseases
10.1016/b978-0-12-386041-5.00004-2 · doi-reference
Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics
10.1016/s1353-8020(09)70800-4 · doi-reference
Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases
10.1016/j.brainresrev.2010.11.004 · doi-reference
Overview of Huntington’s disease models: neuropathological, molecular, and behavioral differences
10.1002/cpns.47 · doi-reference
Post-translational modifications in proteins: resources, tools and prediction methods
10.1093/database/baab012 · doi-reference
Evaluation of post-translational modifications in histone proteins: a review on histone modification defects in developmental and neurological disorders
10.1007/s12038-020-00099-2 · doi-reference
SUMOylation in neurodegenerative diseases
10.1159/000502142 · doi-reference
SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease
10.1016/j.expneurol.2003.07.004 · doi-reference
Biological markers of cognition in prodromal Huntington’s disease: a review
10.1016/j.bandc.2011.07.009 · doi-reference
Neuropsychiatric burden in Huntington’s disease
10.3390/brainsci7060067 · doi-reference
The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery
10.1016/j.cellsig.2011.05.021 · doi-reference
SUMO-targeted ubiquitin ligases (STUbLs) reduce the toxicity and abnormal transcriptional activity associated with a mutant, aggregation-prone fragment of huntingtin
10.3389/fgene.2018.00379 · doi-reference
